But for ChemGenex and Ceflatonin the prospects appear bright. Ceflatonin is a drug intended for the estimated 50 per cent of patients who develop a resistance to Gleevec, the most effective drug available to treat the blood cancer chronic myelogenous leukemia in its advanced stages.
 
[CML]
A group of CMLHope.Com
Subscribe: [EMAIL PROTECTED]
Web Site: http://groups.cmlhope.com 

Reply via email to